Related Experiment Videos
62Cu-labeled bifunctional radiopharmaceuticals with metabolizable ester groups
K Matsumoto1, Y Fujibayashi, Y Arano
1Department of Radiopharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|January 1, 1992
Summary
New bifunctional radiopharmaceuticals labeled with copper-62 (62Cu) were developed. These compounds feature metabolizable ester groups, showing stable chelation and enzymatic hydrolysis, influencing their in vivo behavior.
Area of Science:
- Radiopharmaceutical Chemistry
- Nuclear Medicine
- Bioconjugate Chemistry
Background:
- Bifunctional radiopharmaceuticals are crucial for targeted imaging and therapy.
- Developing stable chelates with controlled in vivo clearance is essential.
- Metabolizable ester groups offer a strategy for modulating pharmacokinetic properties.
Purpose of the Study:
- To synthesize and evaluate novel 62Cu-labeled bifunctional radiopharmaceuticals.
- To assess the bifunctionality, focusing on copper chelation and ester group reactivity.
- To investigate the in vivo behavior influenced by ester hydrolysis.
Main Methods:
- Synthesis of 62Cu-labeled compounds incorporating 4,4-dimethyldithiosemicarbazone chelators and ester functionalities (ethylester, acetylester).
- In vitro stability studies of the copper chelate site.
- In vitro enzymatic hydrolysis assays for the ester groups.
- In vivo biodistribution studies of the 62Cu-labeled radiopharmaceuticals.
Main Results:
- High stability of the 4,4-dimethyldithiosemicarbazone copper chelate was confirmed in vitro.
- Enzymatic hydrolysis of the ethylester and acetylester groups was observed in vitro.
- The in vivo behavior of the 62Cu-labeled compounds appeared to be influenced by ester hydrolysis.
Conclusions:
- The synthesized 62Cu-labeled bifunctional radiopharmaceuticals exhibit stable copper chelation.
- The metabolizable ester groups undergo enzymatic hydrolysis, impacting the compounds' in vivo characteristics.
- These findings support the potential of such radiopharmaceuticals for applications in nuclear medicine.